aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Rating of “Hold” by Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given an average rating of “Hold” by the eight research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company.

A number of equities analysts recently commented on the company. Freedom Capital upgraded aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th. Weiss Ratings upgraded aTyr Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, July 12th.

Hedge Funds Weigh In On aTyr Pharma

Several large investors have recently added to or reduced their stakes in ATYR. UBS Group AG boosted its holdings in shares of aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after buying an additional 2,760,238 shares during the period. GSA Capital Partners LLP grew its position in shares of aTyr Pharma by 272.2% during the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock valued at $2,060,000 after buying an additional 1,923,907 shares during the last quarter. Millennium Management LLC raised its stake in aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock worth $4,829,000 after acquiring an additional 1,231,052 shares during the period. Vanguard Group Inc. raised its stake in aTyr Pharma by 21.0% during the third quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after acquiring an additional 975,887 shares during the period. Finally, AQR Capital Management LLC bought a new position in aTyr Pharma in the fourth quarter worth about $603,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Stock Down 3.3%

ATYR stock opened at $0.55 on Friday. aTyr Pharma has a 52-week low of $0.40 and a 52-week high of $6.50. The stock’s 50 day moving average is $0.53 and its two-hundred day moving average is $0.68. The company has a market capitalization of $54.05 million, a PE ratio of -0.89 and a beta of 0.54.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The company had revenue of $189.56 million for the quarter. As a group, sell-side analysts anticipate that aTyr Pharma will post -0.44 EPS for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.